Kainos Medicine

Kainos Medicine is a drug development company whose core revenue model is discovering drug candidates, advancing them through early clinical stages, and out-licensing them to domestic and global pharmaceutical partners.

The company does not operate manufacturing facilities for products, and its revenue is largely recognized in the form of upfront payments, milestones, and royalties under license agreements.

Its flagship candidate is KM-819, an innovative drug candidate that inhibits the function of FAF1 (Fas-Associated Factor 1), which is involved in the death of dopamine-releasing neurons, and it is being developed as an oral therapy.

The compound is being pursued in two indications simultaneously—Parkinson's disease and multiple system atrophy (MSA)—and for MSA, it is designed as a first-in-class therapy targeting an unmet medical need, working by inhibiting FAF1, which induces cell death, to protect neurons.

The Parkinson's disease indication is in a Phase 2 trial in the United States, while the MSA indication is in a Phase 2/3 trial enrolling a total of 167 clinically diagnosed or probable MSA patients at CHA Bundang Medical Center in Korea.

MSA is a rapidly progressing, fatal neurodegenerative disease characterized by autonomic dysfunction along with parkinsonism or cerebellar ataxia, with an average survival of about eight years after symptom onset, making it an area of significant unmet need.

The company's strategy is to internally develop candidates from discovery through early clinical stages and then commercialize later stages through partnerships with global or large domestic pharmaceutical companies.

Given the nature of a drug-development-only business, revenue is inherently small and volatile, with results directly tied to clinical progress and the timing of any licensing deals.

Kainos Medicine's annual revenue rose steadily from KRW 0.13 billion in 2022 to KRW 0.27 billion in 2023, KRW 0.59 billion in 2024, and KRW 1.17 billion in 2025, though the absolute scale remains small, reflecting a research-and-development-driven business model.

The operating loss peaked at KRW -16.16 billion in 2022 and KRW -16.81 billion in 2023, then narrowed for two consecutive years to KRW -12.33 billion in 2024 and KRW -6.44 billion in 2025.

Net loss attributable to owners followed a similar trajectory, narrowing from KRW -15.88 billion in 2022 to KRW -7.78 billion in 2025.

On a quarterly basis, the operating loss actually widened from KRW -0.945 billion in Q2 2025 (on revenue of KRW 0.176 billion) to KRW -1.506 billion in Q3 2025 (revenue KRW 0.322 billion) and KRW -2.298 billion in Q4 2025 (revenue KRW 0.304 billion).

That trend then reversed in Q1 2026 (revenue KRW 0.370 billion, operating loss KRW -1.012 billion) and Q2 2026 (revenue KRW 0.408 billion, operating loss KRW -1.053 billion), with revenue rising again and the operating loss narrowing noticeably.

The combined net loss attributable to owners over the most recent four quarters (Q3 2025 through Q2 2026) totaled roughly KRW -6.33 billion, consistent with the annual loss-narrowing trend.

On the balance sheet, owners' equity fell sharply from KRW 26.11 billion in 2022 to KRW 11.75 billion in 2023, KRW 1.79 billion in 2024, and KRW 1.15 billion in 2025, while operating cash flow remained negative every year but with a smaller outflow, improving from KRW -14.22 billion in 2023 to KRW -5.92 billion in 2025.

The Parkinson's disease treatment market is generally viewed as an area of long-term expansion driven by population aging.

The global Parkinson's disease treatment market was estimated at $3.5 billion in 2019 and is projected to grow at a compound annual rate of 12.6% to $11.5 billion by 2029, with the United States accounting for 51.5% of the market as of 2019.

MSA has a smaller patient population than Parkinson's disease but remains an area with no approved treatments, meaning successful development could qualify for orphan drug benefits.

Rather than competing directly with large pharmaceutical companies, Kainos Medicine follows the typical business model of a small domestic biotech: conducting early-stage development and generating clinical data, then handing off commercialization to a partner via licensing.

However, the KOSDAQ biotech sector has recently seen a rising number of delisting cases tied to clinical delays and deteriorating balance sheets.

Last year, Cellivery, the first company listed under the growth-potential special listing track, was delisted after an audit opinion disclaimer; antibody drug developer Pharmabcine was delisted for failing revenue requirements amid cumulative losses; and RNA therapeutics developer Olipass was also delisted due to poor clinical progress, financial instability, and an audit disclaimer.

In addition, both NKMax and Kainos Medicine have filed injunctions to suspend the effect of their delisting decisions, with trading halts and related procedures on hold until court rulings are issued.

This pattern reflects both eroding market confidence in technology-special-listed biotech firms and tightening delisting standards by regulators.

The company's near-term trajectory hinges on two separate tracks.

The first is the legal process: the company filed for an injunction with the Seoul Southern District Court to suspend the effect of the delisting decision, and trading remains halted with the scheduled delisting procedures, including the clean-up trading period, on hold until the court issues its ruling.

The outcome of this injunction hearing is the key variable determining whether trading resumes and whether the listing is ultimately maintained.

The second track is the clinical pipeline; the company has stated that it plans to put MSA treatment development on a solid track and then expand into multinational trials including the United States, pursuing global orphan drug designation and early market entry, which it expects could reopen opportunities for collaboration with global pharmaceutical companies and investors.

The company has previously indicated it plans to pursue out-licensing after completing the Phase 2 trial for Parkinson's disease, suggesting that accumulating clinical data could strengthen the basis for future licensing negotiations.

However, all of these plans presuppose smooth capital raising, and the company has a history of repeatedly amending disclosures for third-party-allotted capital increases amid funding difficulties.

Ultimately, the direction of future results is likely to depend heavily on whether the loss-narrowing trend seen over the past four quarters continues, as well as on the court's ruling and the success of ongoing financing efforts.